<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922687</url>
  </required_header>
  <id_info>
    <org_study_id>Ruijin2010No.14</org_study_id>
    <nct_id>NCT01922687</nct_id>
  </id_info>
  <brief_title>Amlodipine Plus/Minus Atorvastatin for Protection of Arteries</brief_title>
  <official_title>Amlodipine Plus/Minus Atorvastatin for Protection of Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute of Hypertension</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Institute of Hypertension</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test the hypothesis that amlodipine plus
      atorvastatin given in a single tablet (Caduet), compared with amlodipine alone (Norvasc), has
      a stronger effect in protection of arterial structure and function.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>flow-mediated dilation (FMD)</measure>
    <time_frame>12-24 weeks</time_frame>
    <description>After 12-week maintenance treatment or at 24-week final visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulse wave velocity (cf-PWV, ba-PWV)</measure>
    <time_frame>12-24 weeks</time_frame>
    <description>After 12-week maintenance treatment or at 24-week final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>6-24weeks</time_frame>
    <description>After 6-week maintenance treatment or at 24-week final visit.
Intolerable adverse events which may or may not be related to the trial treatment, including:
Levels of AST or ALT more than three times the upper limit of normal;
Myalgia symptoms appear with no or only a moderate increase in CK (3 to 10 times above upper limit of normal), but repeated measurements of CK is progressively increasing;
Myalgia symptoms appear, the concentration of CK is 10 times higher than the upper limit of normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ankle-brachial index (ABI)</measure>
    <time_frame>12-24 weeks</time_frame>
    <description>After 12-week maintenance treatment or at 24-week final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>augmentation index (AIx)</measure>
    <time_frame>12-24 weeks</time_frame>
    <description>After 12-week maintenance treatment or at 24-week final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid intima-media thickness (IMT)</measure>
    <time_frame>12-24 weeks</time_frame>
    <description>After 12-week maintenance treatment or at 24-week final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cholesterol level</measure>
    <time_frame>12-24 weeks</time_frame>
    <description>After 12-week maintenance treatment or at 24-week final visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Arterial and Arteriolar Disorders</condition>
  <arm_group>
    <arm_group_label>Amlodipine Plus Atorvastatin (Caduet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amlodipine plus atorvastatin in a single tablet (Caduet, Pfizer, USA) was given once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine (Norvasc)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amlodipine(Norvasc, Pfizer, USA) given once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine plus atorvastatin (Caduet)</intervention_name>
    <arm_group_label>Amlodipine Plus Atorvastatin (Caduet)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine (Norvasc)</intervention_name>
    <arm_group_label>Amlodipine (Norvasc)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women or men, aged from 40 to 75 years;

          2. Women with child-bearing potential should apply an adequate non-pharmacological
             contraceptive technique;

          3. Untreated patients or those on a single antihypertensive drug (except calcium channel
             blocker ) but with an uncontrolled blood pressure on conventional measurement, ranging
             from 140 to 179 mm Hg systolic or from 90 to 109 mm Hg diastolic. The conventional
             blood pressure is the average of 3 consecutive measurements in the sitting position or
             a single visit.

          4. The 24 h ambulatory blood pressure should be at least 130 mm Hg systolic or 80 mm Hg
             diastolic, or higher;

          5. Fasting total cholesterol concentration ranging from 4.14 to 6.22 mmol/L (160 to 240
             mg/dL);

          6. Endothelium-dependent flow-mediated dilatation (FMD) below 10%;

          7. Serum activity of aspartate aminotransferase (AST), alanine aminotransferase (ALT),
             and creatine kinase (CK) should be within the normal range;

          8. Patients should not be on treatment with statins or other lipid-lowering drugs within
             3 months of randomization;

          9. The patients should sign the informed consent form prior to the participation in the
             trial at the first visit;

         10. Patients should be independent and likely to adhere to the study protocol.

        Exclusion Criteria:

          1. Secondary hypertension;

          2. Low-density lipoprotein cholesterol (LDL-C) below 2.59 mmol/L (100mg/dL);

          3. Renal dysfunction defined as eGFR&lt;60ml/min/1.73m2;

          4. Current treatment with specific drugs or diets, such as fibrates (especially
             gemfibrozil), verapamil, amiodarone, grapefruit juice;

          5. Excessive alcohol consumption defined as drinking more than 1L/day;

          6. Stroke within 2 years of randomization or myocardial infarction occurred previous;

          7. Known contra-indications to a dihydropyridine calcium channel blocker or statins;

          8. Any life threatening condition;

          9. Current participation in another trial or trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yan Yang</last_name>
    <phone>64370045</phone>
    <phone_ext>661124</phone_ext>
    <email>jesuisyang@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Institute of Hypertension</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pingjin Gao</last_name>
      <phone>64370045</phone>
      <phone_ext>610903</phone_ext>
      <email>gaopingjin@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Pingjin Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Pingjin Gao</citation>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Institute of Hypertension</investigator_affiliation>
    <investigator_full_name>Yan Yang</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

